<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941222</url>
  </required_header>
  <id_info>
    <org_study_id>CHD187-19</org_study_id>
    <nct_id>NCT04941222</nct_id>
  </id_info>
  <brief_title>Cost-utility Analysis of the Use of the Paro Robotic Seal by Elderly Patients With Moderate or Severe Cognitive Disorders in Institutions: a Randomised Study.</brief_title>
  <acronym>PEPINO</acronym>
  <official_title>Cost-utility Analysis of the Use of the Paro Robotic Seal by Elderly Patients With Moderate or Severe Cognitive Disorders in Institutions: a Randomised Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many residents from establishments for dependent elderly people (EHPAD) have memory disorders&#xD;
      with behavioural problems such as agitation, aggression and anxiety, which make it difficult&#xD;
      to assist them on a daily basis.&#xD;
&#xD;
      Studies have proven the beneficial effect of the therapeutic seal robot PARO® in behavioural&#xD;
      disorders. The present project aims to complement these data with a medico-economic study. At&#xD;
      present, the only study of this type has been carried out in Australia, and is not&#xD;
      transposable to France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost-utility ratio</measure>
    <time_frame>16 weeks after implementation of toilets with/without PARO</time_frame>
    <description>Incremental cost-utility ratio (cost/QALY) from a societal perspective and a time horizon of 16 weeks of the use of the PARO robot</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>With robotic seal &quot;PARO&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without robotic seal &quot;PARO&quot;</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>With robotic seal &quot;PARO&quot;</intervention_name>
    <description>The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks</description>
    <arm_group_label>With robotic seal &quot;PARO&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 70 years of age&#xD;
&#xD;
          -  With moderate or severe neurocognitive disorders of any etiology (Mini Mental State&#xD;
             Examination (MMSE) less than or equal to 20, or not feasible)&#xD;
&#xD;
          -  Resident in EHPAD (establishment for dependent elderly people) or USLD (long-term care&#xD;
             unit ) in permanent accommodation for more than 1 month at inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with presumed life expectancy of less than 3 months&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) not feasible for any reason other than cognitive&#xD;
             impairment (e.g. stroke aphasia), without dementia&#xD;
&#xD;
          -  Known carrier of multi-drug resistant bacteria&#xD;
&#xD;
          -  Carrier of Pace-maker (precautionary advice from manufacturer)&#xD;
&#xD;
          -  Refusal to participate to the study (trusted person, guardian or curator or patient&#xD;
             depending on the patient's mental state)&#xD;
&#xD;
          -  Patient under court protection&#xD;
&#xD;
          -  Prior inclusion in an interventional study that may alter the interpretation of the&#xD;
             results of the analysis&#xD;
&#xD;
          -  Patient not affiliated to a social security system or beneficiary of such a system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stéphanie CHENEAU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stéphanie MARTIN</last_name>
    <phone>0251446483</phone>
    <phone_ext>+33</phone_ext>
    <email>stephanie.martin@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>stéphanie Cheneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARO</keyword>
  <keyword>non-pharmacological intervention</keyword>
  <keyword>economic evaluation</keyword>
  <keyword>Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

